Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

grifols australia pty ltd - normal immunoglobulin, quantity: 5 g - injection, solution - excipient ingredients: sorbitol; human immunoglobulin a; water for injections - replacement therapy indications: - primary immunodeficiency (pi) diseases - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.,immunomodulation indications: - idiopathic thrombocytopaenic purpura (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count. - guillain barr? syndrome - kawasaki disease.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

grifols australia pty ltd - normal immunoglobulin, quantity: 20 g - injection, solution - excipient ingredients: human immunoglobulin a; water for injections; sorbitol - replacement therapy indications: - primary immunodeficiency (pi) diseases - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.,immunomodulation indications: - idiopathic thrombocytopaenic purpura (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count. - guillain barr? syndrome - kawasaki disease.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

grifols australia pty ltd - normal immunoglobulin, quantity: 10 g - injection, solution - excipient ingredients: human immunoglobulin a; water for injections; sorbitol - replacement therapy indications: - primary immunodeficiency (pi) diseases - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.,immunomodulation indications: - idiopathic thrombocytopaenic purpura (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count. - guillain barr? syndrome - kawasaki disease.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

octapharma australia pty ltd - human immunoglobulin g, quantity: 1 g - injection, intravenous infusion - excipient ingredients: human immunoglobulin a; water for injections; glycine - replacement therapy in:,? primary immunodeficiency diseases.,? myeloma or chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent bacterial infections.,? symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.,immunomodulation in:,? idiopathic thrombocytopenic purpura (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count.,? guillain barr? syndrome.,? kawasaki disease.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

octapharma australia pty ltd - human immunoglobulin g, quantity: 5 g - injection, intravenous infusion - excipient ingredients: human immunoglobulin a; water for injections; glycine - replacement therapy in:,? primary immunodeficiency diseases.,? myeloma or chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent bacterial infections.,? symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.,immunomodulation in:,? idiopathic thrombocytopenic purpura (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count.,? guillain barr? syndrome.,? kawasaki disease.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

octapharma australia pty ltd - human immunoglobulin g, quantity: 30 g - injection, intravenous infusion - excipient ingredients: human immunoglobulin a; water for injections; glycine - replacement therapy in:,? primary immunodeficiency diseases.,? myeloma or chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent bacterial infections.,? symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.,immunomodulation in:,? idiopathic thrombocytopenic purpura (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count.,? guillain barr? syndrome.,? kawasaki disease.

Սինգապուր - անգլերեն - HSA (Health Sciences Authority)

blood services group, health sciences authority - immunoglobulin (normal) (human) - injection - 6 g/100 ml - immunoglobulin (normal) (human) 6 g/100 ml

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

octapharma australia pty ltd - normal immunoglobulin, quantity: 3300 mg - injection, solution - excipient ingredients: tributyl phosphate; sodium chloride; water for injections; human immunoglobulin a; glycine; polysorbate 80; sodium acetate - replacement therapy in adults and children in primary immunodeficiency syndromes such as: congenital agammaglobulinaemia and hypogammaglobulinaemia, common variable immunodeficiency (cvid), severe combined immunodeficiencies, igg subclass deficiencies with recurrent infections. replacement therapy in myeloma or chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

octapharma australia pty ltd - normal immunoglobulin, quantity: 1650 mg - injection, solution - excipient ingredients: polysorbate 80; water for injections; glycine; tributyl phosphate; human immunoglobulin a; sodium acetate; sodium chloride - replacement therapy in adults and children in primary immunodeficiency syndromes such as: congenital agammaglobulinaemia and hypogammaglobulinaemia, common variable immunodeficiency (cvid), severe combined immunodeficiencies, igg subclass deficiencies with recurrent infections. replacement therapy in myeloma or chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - normal immunoglobulin, quantity: 3.2 g - injection, solution - excipient ingredients: human immunoglobulin a; glycine; water for injections - evogam is indicated in adults and children for replacement therapy in: primary immunodeficiency disease (pid) and symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.